Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ELOSULFASE ALFA

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Mucopolysaccharidosis IVA (Morquio A) is a rare inherited metabolic disease caused by deficiency of the lysosomal enzyme N… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2017
2017
PURPOSE Elosulfase alfa is an enzyme replacement therapy for the treatment of Morquio A syndrome (mucopolysaccharidosis IVA), a… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
BackgroundThis post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Long-term efficacy and safety of elosulfase alfa enzyme replacement therapy were evaluated in Morquio A patients over 96weeks… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2016
Review
2016
Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive lysosomal storage disease which results in a… Expand
  • table 1
Is this relevant?
Review
2016
Review
2016
INTRODUCTION Morquio A syndrome is a rare, autosomal recessive, lysosomal storage disorder caused by a deficiency in the enzyme N… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 3
Is this relevant?
2015
2015
Lysosomal storage diseases arise because of genetic mutations that result in nonfunctioning or dysfunctional lysosomal enzymes… Expand
Is this relevant?
Review
2014
Review
2014
Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an inherited, lysosomal storage disorder caused by… Expand
Is this relevant?